Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus
Warren Floyd, Matthew Pierpoint, Chang Su, Rutulkumar Patel, Lixia Luo, Katherine Deland, Amy J. Wisdom, Daniel Zhu, Yan Ma, Suzanne Bartholf DeWitt, Nerissa T. Williams, Alexander L. Lazarides, Jason A. Somarelli, David L. Corcoran, William C. Eward, Diana M. Cardona, David G. Kirsch
Warren Floyd, Matthew Pierpoint, Chang Su, Rutulkumar Patel, Lixia Luo, Katherine Deland, Amy J. Wisdom, Daniel Zhu, Yan Ma, Suzanne Bartholf DeWitt, Nerissa T. Williams, Alexander L. Lazarides, Jason A. Somarelli, David L. Corcoran, William C. Eward, Diana M. Cardona, David G. Kirsch
View: Text | PDF
Research Article Oncology

Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus

  • Text
  • PDF
Abstract

ATRX is one of the most frequently altered genes in solid tumors, and mutation is especially frequent in soft tissue sarcomas. However, the role of ATRX in tumor development and response to cancer therapies remains poorly understood. Here, we developed a primary mouse model of soft tissue sarcoma and showed that Atrx-deleted tumors were more sensitive to radiation therapy and to oncolytic herpesvirus. In the absence of Atrx, irradiated sarcomas had increased persistent DNA damage, telomere dysfunction, and mitotic catastrophe. Our work also showed that Atrx deletion resulted in downregulation of the CGAS/STING signaling pathway at multiple points in the pathway and was not driven by mutations or transcriptional downregulation of the CGAS/STING pathway components. We found that both human and mouse models of Atrx-deleted sarcoma had a reduced adaptive immune response, markedly impaired CGAS/STING signaling, and increased sensitivity to TVEC, an oncolytic herpesvirus that is currently FDA approved for the treatment of aggressive melanomas. Translation of these results to patients with ATRX-mutant cancers could enable genomically guided cancer therapy approaches to improve patient outcomes.

Authors

Warren Floyd, Matthew Pierpoint, Chang Su, Rutulkumar Patel, Lixia Luo, Katherine Deland, Amy J. Wisdom, Daniel Zhu, Yan Ma, Suzanne Bartholf DeWitt, Nerissa T. Williams, Alexander L. Lazarides, Jason A. Somarelli, David L. Corcoran, William C. Eward, Diana M. Cardona, David G. Kirsch

×

Figure 7

Atrx deletion suppresses type I IFN signaling in a CGAS/STING-dependent manner.

Options: View larger image (or click on image) Download as PowerPoint
Atrx deletion suppresses type I IFN signaling in a CGAS/STING-dependent ...
(A) Hallmark pathway gene set enrichment analysis of RNA-Seq data comparing 3 Atrx KO isogenic cell lines treated with ISD to 3 Atrx WT isogenic cell lines treated with ISD. (B) RT-PCR of Ifnb1 for Atrx WT (n = 3) and Atrx KO (n = 3) isogenic cell line pairs transfected with ISD at a concentration of 3 μg/mL and harvested 24 hours after treatment. Statistical analysis was performed using a ratio paired t test. All data points represent biological replicates. (C) RT-PCR quantification of Ifnb1 expression after ISD stimulation for an Atrx WT and Sting WT sarcoma cell line without or with CRISPR-mediated knockout of Atrx alone or Sting alone. These experiments were performed using 3 technical replicates per experimental condition and the resulting log fold–change value is shown. (D) RT-PCR of Ifnb1 for Atrx isogenic cell line pair 1 treated for 24 hours with 100 μg/mL DMXAA, a potent STING agonist and cGAMP analogue. Each dot represents a separate experimental repeat of the RT-PCR assay (n = 4 per arm). Statistical analysis was performed using an unpaired t test with Welch’s correction. (E) RT-PCR of Ifnb1 for Atrx isogenic cell line pairs (n = 4) treated with Poly(I:C) at a concentration of 1 μg/mL and harvested at 24 hours. Statistical analysis was performed using a ratio paired t test. All data points represent biological replicates. (F) RT-PCR quantification of 4 other ISGs downstream of the CGAS pathway for Atrx isogenic cell line pairs (n = 3) harvested 24 hours after transfection with ISD. Statistical analysis was performed using an unpaired t test with Welch’s correction. (G) RT-PCR quantification of IFNB1 for the 143B human sarcoma cell line with or without ATRX KO harvested 24 hours after treatment with oncolytic herpesvirus HSV-60 DNA. Each dot represents a separate experimental repeat of the RT-PCR assay (n = 3 per arm). Statistical analysis was performed using an unpaired t test with Welch’s correction. (H) RT-PCR of IFNB1 for 143B human sarcoma cell line with or without ATRX KO treated for 24 hours with 100 μg/mL cGAMP. Each dot represents a separate experimental repeat of the RT-PCR assay (n = 3 per arm). Statistical analysis was performed using an unpaired t test with Welch’s correction. (I and J) ELISA for cGAMP was performed using either mouse (I) or human (J) ATRX isogenic cell lines in triplicate. Raw values were fit to a standard curve with the use of the ELISATriple Plate software from Cayman. Each dot represents a technical replicate of the experiment, error bars showing SEM. Statistical analysis was performed using an unpaired t test with Welch’s correction for both I and J.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts